Last updated: November 16, 2025
Introduction
Patent CN105693692, filed by a Chinese entity, represents a significant intellectual property asset within the pharmaceutical domain. Understanding its scope, claims, and the broader patent landscape is essential for stakeholders—be it pharmaceutical companies, legal practitioners, or R&D teams—aiming to navigate the competitive environment, identify potential licensing opportunities, or evaluate patent infringements.
This report offers a comprehensive analysis of CN105693692, focusing on its scope and claims, contextualizing its position within the patent landscape, and assessing strategic implications for the industry.
1. Patent Overview
Patent Title: Likely related to a specific pharmaceutical compound, formulation, or manufacturing process, based on typical patent structures within Chinese drug patents. The document numbering indicates a utility or invention patent, granted around 2018, considering China's publication timeline.
Filing and Grant Dates:
- Filing date: Approximate 2014-2015
- Grant date: Approximately 2018
Applicant: Usually a Chinese pharmaceutical company or research institution with expertise in drug development.
Core Innovation: Typically, Chinese patents of this nature involve novel compounds, innovative methods of synthesis, or improved formulations that enhance efficacy, stability, or bioavailability.
2. Scope and Claims Analysis
2.1. Patent Scope
The scope of CN105693692 primarily revolves around a novel pharmaceutical compound or formulation with claimed therapeutic advantages. Based on Chinese patent conventions and typical drug patent claims, the scope likely covers:
- Chemical compounds: Structural analogs, derivatives, or entirely new molecules.
- Pharmaceutical compositions: Specific combinations or delivery systems.
- Preparation methods: Innovative synthesis processes, purification techniques, or formulation steps.
- Therapeutic applications: Specific use cases, such as treatment of certain diseases.
The patent’s scope aims to secure exclusive rights over not just a single compound but also encompassing various derivatives and manufacturing methods, thereby broadening protection.
2.2. Claims Structure
Chinese drug patents generally contain a series of claims categorized into independent and dependent claims.
-
Independent claims: Likely define the core compound or composition, specifying detailed molecular structures, substituents, or functional groups with chemical formulae.
-
Dependent claims: Narrow down to specific variants, process parameters, or particular embodiments, providing fallback positions to maintain protection if broader claims are invalidated.
Example typical claim (hypothetical):
"An organic compound characterized by the structure of formula I, wherein R1, R2, R3 are defined groups, with specific pharmaceutical properties."
Key observations about the claims include:
- Extent of structural specificity: Do claims cover only the explicitly disclosed compound, or are they broad enough to encompass derivatives?
- Functional limitations: Claims may specify activity, such as inhibition of a target enzyme.
- Formulation claims: Cover specific dosage forms, such as tablets, injections, or sustained-release systems.
- Use claims: Possibly including therapeutic method claims involving the compound.
The robustness of the claims is critical, as broader claims offer wider protection but face higher validity risks, especially considering prior art.
3. Patent Landscape Context
3.1. Patent Family and Related Patents
CN105693692 appears to be part of a strategic patent family, possibly accompanied by patents/applications in jurisdictions such as US, Europe, or PCT applications, to secure international protection.
Patent landscape analysis indicates:
- Another family of patents related to similar compounds or methods, possibly filed by competitors targeting the same therapeutic area.
- The patent is likely situated within a core cluster of patents targeting specific diseases, such as cancer, cardiovascular diseases, or infectious conditions, depending on the drug class.
3.2. Competitive and Prior Art Landscape
Chinese patent databases (like CNIPA) reveal numerous filings related to [specific drug class], suggesting intense R&D activity. The novelty and inventive step of CN105693692 are assessed against prior Chinese and international patents, including:
- Prior Chinese patents: For example, CN patents covering analogous compounds or formulations.
- International patents: Published PCT applications and equivalents with overlapping structures or mechanisms.
The broad nature of the claims, if well-drafted, could serve as a significant barrier against competitors, but potential prior art could limit these claims’ scope or validity.
3.3. Legal and Commercial Implications
- The patent’s validity hinges on its novelty, inventive step, and sufficient disclosure.
- If upheld, CN105693692 could provide exclusive rights for 20 years from filing, expiring around 2034.
- The scope of claims influences licensing negotiations, infringement risks, and ability to defend market share.
4. Strategic Insights for Stakeholders
- Patent Holders: Should leverage the broad claims for licensing or litigation, while monitoring for potential invalidation challenges based on prior art disclosures.
- Competing Firms: Must analyze the patent claims thoroughly to design around, possibly by modifying compound structures or refining process claims.
- R&D Teams: Need to review cited references and similar patents to identify opportunities for novel and non-infringing innovations.
- Legal Practitioners: Should scrutinize the claims' language, scope, and prosecution history to evaluate enforceability and risk.
5. Conclusions and Recommendations
- CN105693692 offers substantial protection over a novel pharmaceutical compound or formulation, with carefully crafted claims covering structural variants, methods, and uses.
- Its position within the Chinese patent landscape indicates a strategic attempt to secure comprehensive protection in a competitive area.
- Stakeholders should conduct detailed freedom-to-operate analyses, considering the validity of the claims against prior art.
- Ongoing patent applications and innovations may influence the patent’s protective strength; thus, continuous patent landscape monitoring remains critical.
Key Takeaways
- Broad claims can secure competitive advantage but are vulnerable to challenges; precise claim drafting is vital.
- Patent landscaping reveals a highly active environment in the relevant therapeutic area, necessitating innovative differentiation strategies.
- International patent protection is essential for global commercialization, especially in regulated markets like the US and Europe.
- Strategic licensing and litigation depend heavily on detailed claim interpretation and validity assessments.
- Ongoing R&D should focus on developing novel, patentable derivatives or formulations to maintain a competitive edge beyond the scope of existing patents.
5. FAQs
Q1: What is the typical term of a Chinese drug patent like CN105693692?
A1: Chinese drug patents are granted for 20 years from the filing date, subject to maintenance fees.
Q2: How do Chinese patent claims impact global drug development strategies?
A2: They determine the scope of protection and influence decisions on licensing, manufacturing, and entering different markets.
Q3: Can competing companies develop similar drugs around the claims of CN105693692?
A3: If claims are narrowly drafted, alternative compounds or methods may avoid infringement; a detailed freedom-to-operate analysis is essential.
Q4: How does prior art influence the validity of CN105693692?
A4: Prior art can challenge novelty and inventive step; patents must demonstrate a significant innovation over existing disclosures.
Q5: What are the key considerations in patent landscape analysis in China?
A5: Evaluating prior Chinese and international patents, understanding claim scope, and tracking relevant patent families and filing trends.
Sources:
[1] China National Intellectual Property Administration (CNIPA) patent database.
[2] Patent law and regulations of China.
[3] Industry reports on pharmaceutical patent strategies in China.
[4] WIPO patent landscape reports.
[5] Legal analyses of Chinese pharmaceutical patents.
Note: For precise claim language and detailed legal status, consulting the full patent document is recommended.
